Faron Pharmaceuticals Limited (AIM:FARN) chief medical officer Dr Petri Bono speaks with Proactive's Stephen Gunnion about the promising interim results from the phase II BEXMAB trial. This trial targets relapsed and refractory myelodysplastic syndrome (MDS) with their anti-Clever-1 antibody, bexmarilimab.
Bono highlighted that BEXMAB treatment combined with azacitidine showed a median survival of 13.5 months, significantly surpassing the historical survival rate of 5 to 6 months. He noted an exceptional 80% overall response rate in patients who had no other treatment options. These results represent significant progress for this challenging patient population.
Additionally, he shared that detailed clinical, translational, and safety findings would be presented at the American Society of Hematology annual meeting in December 2024. He confirmed that the full phase II results are expected by the end of Q1 2025, with enrollment ongoing in the US, Finland, and soon the UK.